FOXO4-DRI

FOXO4-DRI is a laboratory-designed peptide that belongs to a class of experimental compounds called senolytics, agents intended to selectively eliminate senescent cells. It is not a hormone, not a growth factor and not a supplement. It is an interfering peptide: a molecule whose only job is to get inside a cell and physically block a protein-protein interaction.

The name encodes the design. FOXO4 refers to Forkhead box protein O4, a transcription factor that is unusually abundant in senescent cells. DRI stands for D-retro-inverso, a chemical strategy in which the amino acid sequence is written backwards and each residue is swapped from the natural L-form to the mirror-image D-form. The result keeps much of the three-dimensional shape of the original fragment while becoming far harder for the body's proteases to chop up.

The publicly reported construct is 46 residues long and has two functional halves. One half is derived from the FOXO4 forkhead domain and acts as the decoy that competes for binding to p53. The other half is a cationic sequence derived from the HIV TAT protein, a well-established cell-penetrating tag that allows a molecule this large to cross the plasma membrane. From that sequence, the molecular weight calculates to roughly 5,358 g/mol with the formula C₂₂₈H₃₈₈N₈₆O₆₄. Figures circulating on vendor pages vary, sometimes because of salt forms and sometimes because of simple transcription errors, so any single number should be treated as approximate.

In commercial listings the same molecule is sometimes relabeled Proxofim. The naming is marketing, not a sign of a different or more developed compound. Readers comparing it to other compounds discussed in our overview of peptides studied for anti-aging purposes should note that FOXO4-DRI sits at the very earliest end of that spectrum: it is a research tool, and the honest description of its development stage is preclinical.

A senescent cell is a cell that has permanently stopped dividing but has not died. Senescence is triggered by stresses such as DNA damage, telomere attrition, oncogene activation, radiation or chemotherapy. In the short term it is protective: a damaged cell that cannot divide cannot become a tumor, and the immune system normally clears it.

The problem is accumulation. With age, and at the sites of many chronic diseases, senescent cells build up faster than they are removed. They are metabolically active and secrete a cocktail of inflammatory cytokines, chemokines and proteases known as the senescence-associated secretory phenotype (SASP). The SASP can push neighboring healthy cells toward senescence, degrade extracellular matrix and sustain low-grade chronic inflammation.

What makes senescent cells a drug target is a specific vulnerability. Work from Zhu and colleagues, published in Aging Cell in 2015, showed that senescent cells survive by upregulating pro-survival networks the authors called senescent cell anti-apoptotic pathways (SCAPs). Silencing key nodes in those networks killed senescent cells while sparing proliferating and quiescent cells. That finding established the central premise of the field: senescent cells are not merely passive debris, they are actively holding off their own death, and that dependency can be exploited.

FOXO4-DRI is one attempt to exploit it, and it takes an unusually targeted route. Rather than inhibiting a broad survival kinase or a BCL-2 family protein, it was designed around a single interaction that appears to be specific to senescent cells. Whether a narrow target translates into fewer off-target effects in a whole organism remains an open question, and it is not one that mouse data can settle. Readers interested in how senescence intersects with other research peptides may find context in our guides to Epithalon and MOTS-c, which target telomerase biology and mitochondrial signaling respectively rather than senescent cell clearance.

The proposed mechanism centers on a single partnership: FOXO4 and p53. The tumor suppressor p53 is a decision-making hub. Depending on where it sits in the cell and which partners it binds, p53 can arrest the cell cycle, drive DNA repair, or trigger apoptosis.

In the model proposed by Baar and colleagues, senescent cells raise FOXO4 levels, and FOXO4 holds p53 in the nucleus in a configuration that supports growth arrest rather than cell death. In other words, FOXO4 acts as a chaperone that keeps p53 working as a brake instead of an executioner. This is what allows a badly damaged cell to persist indefinitely in the senescent state.

FOXO4-DRI is built to interrupt that arrangement. As a decoy fragment, it competes for the p53 binding surface. When the FOXO4-p53 interaction is broken, the authors reported that p53 is excluded from the nucleus and accumulates in the cytoplasm, where it engages intrinsic, caspase-dependent apoptosis. The selectivity argument follows from the biology: healthy cells have far less FOXO4 and therefore far less of the interaction to disrupt, so in principle they are left alone.

That model has since been examined at atomic resolution. A 2025 study in Nature Communications by Bourgeois, Spreitzer and colleagues used solution NMR to build structural models of the p53 transactivation domain bound to both the FOXO4 forkhead domain and to FOXO4-DRI. They reported that FOXO4-DRI, itself disordered, binds the intrinsically disordered transactivation domain of p53 and forms a transiently folded complex. This is a meaningful refinement: it identifies the actual binding partner surface and shows the interaction is dynamic rather than a rigid lock and key.

Work in endothelial cells adds a downstream picture. Hu and colleagues, publishing in Frontiers in Bioengineering and Biotechnology in early 2026, reported that FOXO4-DRI promotes apoptosis of senescent endothelial cells through p53, BCL-2 and caspase-3 signaling. Converging mechanistic detail is genuinely useful, but mechanism is not efficacy, and neither of these studies involved treating a human being.

A straightforward peptide made of natural L-amino acids has a short life in the body. Proteases in plasma, in the interstitial space and inside cells recognize L-peptide backbones and cleave them, often within minutes. For a molecule that has to survive long enough to cross a membrane and compete with an endogenous protein for a binding site, that is a serious design problem.

The retro-inverso strategy is a classic workaround. Two changes are applied at once. First, the sequence is reversed, read from C-terminus to N-terminus. Second, every residue is switched from the L-enantiomer to the D-enantiomer. Because the two inversions partly cancel one another geometrically, the side chains end up in roughly the same spatial arrangement as in the parent peptide, so the binding surface is largely preserved. But proteases, which are stereospecific, no longer recognize the backbone. The practical consequence is a substantially longer biological half-life.

The second design element is the cell-penetrating tag. The FOXO4-p53 interaction happens inside the cell, so a peptide that cannot cross the membrane is inert no matter how well it binds. The cationic TAT-derived sequence attached to the FOXO4 fragment provides that entry. This is a standard tool in cell biology, and it comes with a standard caveat: cell-penetrating peptides are not tissue-selective. They enter many cell types, which means biodistribution in a whole organism is difficult to control and difficult to predict from culture work.

It is worth being clear about what the retro-inverso design does and does not buy. It buys stability against degradation. It does not buy oral bioavailability, it does not confer tissue targeting, and it does not reduce the chance that the immune system recognizes a 46-residue synthetic construct as foreign. Stability can also cut both ways: a molecule that resists clearance is a molecule whose off-target effects may persist longer.

Nearly everything written about FOXO4-DRI traces back to a single paper: Baar MP, Brandt RMC, Putavet DA and colleagues, Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging, published in Cell in March 2017 (volume 169, issue 1, pages 132 to 147). The study came from Peter de Keizer's group, and it is a substantial piece of work. It deserves to be read for what it reports rather than for what it has been made to represent.

The paper first identified FOXO4 as a pivot in senescent cell viability, then designed the FOXO4 peptide to perturb the FOXO4-p53 interaction. In senescent cells, the authors reported that this selectively caused p53 nuclear exclusion and cell-intrinsic apoptosis.

The in vivo work used three mouse settings. In mice given doxorubicin, a chemotherapy agent that induces widespread senescence, the authors reported that the peptide neutralized doxorubicin-induced chemotoxicity under conditions where it was well tolerated. They then moved to aging: in fast-aging Xpg-deficient mice and in naturally aged mice, the peptide restored fitness, fur density and renal function.

Those three outcomes are the source of the striking before-and-after images that circulated widely in 2017 and still circulate today. They are real published findings in mice, and they are the reason the compound attracted attention. They are also, read carefully, a narrow set of endpoints. Restored fur density and improved renal function markers in aged mice are encouraging signals in a model organism. They are not a demonstration that a human being becomes healthier, and the paper itself does not claim otherwise.

Two further caveats belong with any citation of this study. First, mouse aging models, particularly accelerated-aging mutants such as Xpg-deficient animals, model specific damage pathways rather than the whole of human aging. Second, the published mouse administration regimens were designed for mice. They are not human dosing guidance, and this guide does not reproduce them.

FOXO4-DRI did not disappear after 2017, but the published work that followed has mostly narrowed rather than broadened. Instead of attempts to repeat the whole-animal healthspan experiment, later studies have examined specific tissues and specific cell types.

In 2020, Zhang C, Xie Y, Chen H and colleagues published a study in Aging (volume 12, issue 2, pages 1272 to 1284) on male late-onset hypogonadism. They reported that FOXO4 is expressed in human Leydig cells and that its nuclear translocation in older men was related to decreased testosterone synthesis. By disrupting the FOXO4-p53 interaction, FOXO4-DRI selectively induced apoptosis in senescent Leydig cells, and in naturally aged mice it improved the testicular microenvironment and alleviated age-related testosterone secretion insufficiency. This remains a mouse and human-tissue study, not a clinical result.

In 2021, Huang Y, He Y, Makarcyzk MJ and Lin H published in Frontiers in Bioengineering and Biotechnology on a different and quite practical question: cartilage cell manufacturing. Human chondrocytes expanded in culture accumulate senescent cells, which degrades their usefulness for tissue engineering. The authors reported that the senolytic peptide selectively removed senescent cells from in vitro expanded human chondrocytes. This is human cell work, and it is a reminder that the most credible near-term application of a senolytic peptide may be in the laboratory dish rather than in a patient.

In early 2026, Hu Z, Li F and colleagues reported in the same journal that FOXO4-DRI regulates endothelial cell senescence through p53 signaling, with apoptosis of senescent endothelial cells proceeding via BCL-2 and caspase-3. Alongside the 2025 Nature Communications structural work, the picture is of a field refining the mechanism of a tool compound.

What is conspicuously missing is the translational step. Nine years after the original paper, the compound has not produced a published human pharmacokinetic study, a published formal toxicology package, or a registered trial. In drug development that gap is informative in itself.

The short answer is no. There is human cell evidence, most clearly in the 2021 chondrocyte study, where FOXO4-DRI removed senescent cells from human chondrocytes expanded in culture. There is no human clinical evidence. As of October 2026, a search of trial registries returns no completed, ongoing or registered interventional study of FOXO4-DRI in people.

That means several specific things are unknown, and it is worth naming them rather than glossing over them. Nobody has published what dose range is tolerated in humans. Nobody has published its human half-life, distribution or clearance route. Nobody has characterized its immunogenicity in humans, which matters for a synthetic D-amino acid construct carrying a viral-derived cell-penetrating tag. Nobody has conducted a controlled safety assessment in people with the comorbidities typical of the ages at which senolytics are proposed to be useful. And no agency has evaluated a manufacturing or purity standard for it.

The compound is also not approved by the FDA, the EMA or any comparable regulator for any human indication. Material sold online is sold for laboratory research use, and that label is not a technicality. It means the product has not been assessed for sterility, endotoxin content, peptide identity or impurity profile to the standards that apply to injectable medicines. Independent testing of grey-market peptides has repeatedly found discrepancies between label and content, and a peptide intended to trigger apoptosis is a poor candidate for tolerating a manufacturing error.

Our general discussion of how to think about peptide safety applies here with unusual force. For most research peptides the question is whether animal signals will translate. For FOXO4-DRI the prior question has not been answered: we do not yet know what a single human exposure does.

Medical disclaimer: this section is educational. Nothing here should be read as a suggestion that FOXO4-DRI can or should be used in humans. Discuss any health concern with a qualified healthcare professional.

Because no human safety data exist, the risks below are reasoned from the biology rather than observed in trials. They are theoretical, and that is precisely why they matter: in the absence of data, mechanism is the only guide available.

Senescence is not uniformly harmful. Senescence evolved as an anti-cancer brake and plays constructive roles in wound healing, tissue remodeling and limiting fibrosis in some contexts. Broadly removing senescent cells removes the useful ones along with the harmful ones. The net effect in a given tissue, at a given age, in a given disease state, is not predictable from first principles.

Interfering with p53 is not a small intervention. The proposed mechanism works by changing where p53 sits and what it does. p53 is the single most important tumor suppressor in human biology. A molecule that modulates its localization has, at minimum, a theoretical oncological risk profile that would need to be excluded by formal carcinogenicity work. None has been published.

Delivery is non-selective. A cationic cell-penetrating tag enters many cell types. Apoptosis triggered in the wrong tissue is not a mild adverse event, and the 2017 paper itself framed its in vivo findings as occurring under conditions where the peptide was tolerated, which implies a window rather than an absence of toxicity.

Immunogenicity and injection-site reactions. Synthetic peptides of this size can provoke antibody responses and local inflammatory reactions. Neither has been characterized for this molecule in humans.

Product quality risk. Unregulated injectable material carries risks of contamination, incorrect identity, incorrect quantity and endotoxin exposure that are entirely independent of the pharmacology.

This article deliberately provides no dosage and no protocol. Publishing one for a compound with zero human safety data would be indefensible, and the absence here is intentional rather than an omission.

FOXO4-DRI is not the only senolytic strategy, and it is not the furthest along. Kirkland and Tchkonia, reviewing the field in the Journal of Internal Medicine in 2020, note that the first senolytic drugs, dasatinib, quercetin, fisetin and navitoclax, were discovered using a hypothesis-driven approach based on the pro-survival pathways that senescent cells depend on.

The combination of dasatinib plus quercetin has reached small early-phase human studies. Hickson and colleagues, in EBioMedicine in 2019, reported an open-label study in nine participants with diabetic kidney disease given a short oral course, with senescent cell burden in adipose tissue reduced when reassessed days after dosing. Justice and colleagues, also in EBioMedicine in 2019, reported a first-in-human, open-label pilot study of intermittent dasatinib plus quercetin in 14 participants with idiopathic pulmonary fibrosis, with 100% retention and no discontinuation of the drug combination. Both are small, uncontrolled, short pilot studies. They establish feasibility and target engagement, not clinical benefit.

Fisetin, a flavonoid found in strawberries and other plants, was characterized by Yousefzadeh and colleagues in EBioMedicine in 2018, who reported that administering it to wild-type mice late in life restored tissue homeostasis, reduced age-related pathology and extended median and maximum lifespan. Those are mouse lifespan data. Fisetin's human evidence base is still developing through early-phase studies.

The comparison is not flattering to the peptide. FOXO4-DRI has the most elegant and most specific proposed mechanism of the group, and the weakest translational record. Dasatinib is a prescription oncology drug with its own toxicity profile, so none of these alternatives should be read as a safe consumer option either.

As of October 2026, FOXO4-DRI is a research compound. It is sold by chemical suppliers for laboratory use and is not approved by any major regulator for human administration. Legal status varies by jurisdiction: in most countries the peptide itself is not a controlled substance, but marketing it for human use, or administering it, falls under medicines legislation and is generally not permitted. Anyone encountering it offered as a clinical service should treat that as a significant warning sign rather than a sign of early access.

Scientifically, the picture is of a well-conceived tool compound whose biology is still being worked out. The 2025 NMR structural work and the 2026 endothelial cell study both deepen understanding of how the molecule engages p53. The 2021 human chondrocyte study points toward a genuinely plausible near-term use: cleaning senescent cells out of cell populations grown for tissue engineering, where the peptide acts on cells in a dish and never enters a patient.

What would change the picture is unglamorous and specific. A published formal toxicology package. Pharmacokinetic and biodistribution data in a large animal species. A manufacturing standard. Then a registered Phase 1 study with defined safety endpoints. Until at least the first of those exists, claims about human rejuvenation are extrapolation from mouse fur and mouse kidney markers.

For readers mapping the broader landscape, it is reasonable to place FOXO4-DRI as the most mechanistically interesting and least clinically supported entry in the senolytic category. Compounds such as those covered in our Epithalon guide occupy different positions on the same evidence axis, and our comparison of peptides researched for anti-aging applications sets out how to read that axis.

Disclaimer: This article is for educational purposes only and is not medical advice. FOXO4-DRI is a research peptide that is not approved for human use. Consult a qualified healthcare professional before making any health decision. Legal status varies by country, and preclinical findings in animals do not reliably predict outcomes in humans.